Theravance Biopharma (NASDAQ:TBPH) Stock Passes Above 50-Day Moving Average - Should You Sell?

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $9.30 and traded as high as $9.44. Theravance Biopharma shares last traded at $9.35, with a volume of 167,372 shares trading hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $13.75.

Theravance Biopharma Price Performance

The business has a 50 day moving average of $9.31 and a 200 day moving average of $9.04. The firm has a market capitalization of $464.33 million, a price-to-earnings ratio of -9.29 and a beta of 0.15.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.26). The company had revenue of $18.75 million during the quarter, compared to the consensus estimate of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. As a group, equities analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Remove Ads

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 309,565 shares of the company's stock, valued at approximately $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently modified their holdings of TBPH. Aquatic Capital Management LLC bought a new position in Theravance Biopharma in the fourth quarter valued at approximately $25,000. Quantbot Technologies LP acquired a new stake in shares of Theravance Biopharma during the third quarter worth $60,000. KLP Kapitalforvaltning AS bought a new stake in Theravance Biopharma in the 4th quarter valued at $69,000. Teacher Retirement System of Texas acquired a new position in Theravance Biopharma in the 4th quarter worth $103,000. Finally, ClearAlpha Technologies LP bought a new position in Theravance Biopharma during the 4th quarter worth about $109,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.